• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    68 Biggest Movers From Yesterday

    3/16/22 5:24:45 AM ET
    $AGFY
    $AHPI
    $ANIP
    $ASLE
    Farming/Seeds/Milling
    Consumer Staples
    Industrial Specialties
    Health Care
    Get the next $AGFY alert in real time by email

    Gainers

    • Sonim Technologies, Inc. (NASDAQ:SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie Talkie in Microsoft Teams.
    • Incannex Healthcare Limited (NASDAQ:IXHL) shares climbed 55% to close at $35.50 on Tuesday after jumping 54% on Monday. Incannex Healthcare recently completed a preliminary analysis of data from its Phase 2 trial of a cannabinoid combination product, IHL-42X, for obstructive sleep apnoea (OSA).
    • Jaguar Health, Inc. (NASDAQ:JAGX) gained 44.5% to settle at $0.5453. Jaguar Health recently posted FY21 sales of $15.719 million.
    • RLX Technology Inc. (NASDAQ:RLX) shares climbed 40.2% to close at $1.71. RLX Technology, last week, reported Q4 earnings results.
    • CooTek (Cayman) Inc. (NYSE:CTK) shares rose 36.9% to close at $0.27 after reporting Q4 results.
    • Hour Loop Inc (NASDAQ:HOUR) gained 31.3% to settle at $3.99.
    • Sonendo Inc (NASDAQ:SONX) gained 30.8% to close at $4.45.
    • Rapid Micro Biosystems Inc (NASDAQ:RPID) gained 26.2% to settle at $7.57.
    • Kaival Brands Innovations Group, Inc (NASDAQ:KAVL) gained 25.9% to settle at $1.75.
    • Kingsoft Cloud Holdings Limited (NASDAQ:KC) surged 25.4% to close at $3.21. JP Morgan, on Monday, downgraded the stock from Neutral to Underweight and announced a $3.5 price target.
    • Revelation Biosciences Inc (NASDAQ:REVB) gained 22.6% to close at $1.25 after the company announced the completion of enrollment and dosing in Phase 2b viral challenge study to evaluate the efficacy of intranasal REVTx-99 for the preventive treatment of H3N2 influenza.
    • New Oriental Education & Tech Grp (NYSE:EDU) gained 22.6% to settle at $1.06.
    • TherapeuticsMD Inc (NASDAQ:TXMD) gained 22.2% to close at $0.33.
    • Palisade Bio Inc (NASDAQ:PALI) climbed 22% to close at $1.18.
    • Janone Inc (NASDAQ:JAN) gained 21.9% to settle at $3.39.
    • Lion Group Holding Ltd – ADR (NASDAQ:LGHL) gained 21.4% to close at $1.05.
    • DocGo Inc (NASDAQ:DCGO) gained 21.1% to settle at $7.46. The company recently posted upbeat quarterly sales.
    • Sunworks Inc (NASDAQ:SUNW) climbed 20.6% to close at $3.04. Sunworks, last week, reported worse-than-expected Q4 adjusted EPS results.
    • Summer Infant, Inc. (NASDAQ:SUMR) gained 20.6% to settle at $8.50.
    • Shift Technologies Inc (NASDAQ:SFT) climbed 20.6% to close at $1.93 following quarterly results.
    • Allied Healthcare Products Inc (NASDAQ:AHPI) gained 20.5% to settle at $3.35.
    • Butterfly Network, Inc. (NYSE:BFLY) gained 20.3% to close at $4.50. FUJIFILM Sonosite recently filed patent infringement lawsuit against Butterfly Network.
    • Meta Materials Inc (NASDAQ:MMAT) climbed 19.9% to settle at $1.69.
    • Clearside Biomedical, Inc. (NASDAQ:CLSD) gained 19.7% to settle at $2.49.
    • Hall of Fame Resort & Entertainment Co (NASDAQ:HOFV) climbed 18.9% to close at $0.96.
    • Cerberus Cyber Sentinel Corp (NASDAQ:CISO) gained 18.4% to close at $5.19.
    • Modiv Inc (NYSE:MDV) gained 18.4% to settle at $20.71, possibly amid continued post-IPO volatility.
    • Qudian Inc – ADR (NYSE:QD) gained 18.4% to close at $0.75.
    • Procept Biorobotics Corp (NASDAQ:PRCT) climbed 18.4% to settle at $29.30. PROCEPT BioRobotics recently posted a Q4 loss of $0.42 per share.
    • Hollysys Automation Technologies Ltd. (NASDAQ:HOLI) climbed 17.7% to close at $15.76. The state-owned operator of Beijing’s railway is weighing an offer for Hollysys Automation, Bloomberg reported.
    • CIRCOR International, Inc. (NYSE:CIR) gained 17.3% to close at $27.63.
    • Big Lots, Inc. (NYSE:BIG) gained 15.4% to settle at $36.93 after Mill Road Capital in a 13D filing said it believes a sale process could maximize value for shareholders.
    • Tencent Music Entertainment Group (NYSE:TME) surged 14.7% to settle at $3.58.
    • Sunshine Biopharma, Inc. (NASDAQ:SBFM) gained 14.3% to close at $3.27. Sunshine Biopharma announced closing of $8.0 million private placement priced at-the-market.
    • Fossil Group, Inc. (NASDAQ:FOSL) climbed 13.6% to close at $9.17. Fossil Group, last week, reported Q4 earnings results.
    • Cano Health, Inc. (NYSE:CANO) gained 13.6% to settle at $6.03 following Q4 results.
    • Co-Diagnostics, Inc. (NASDAQ:CODX) rose 13.1% to close at $5.69. Co-Diagnostics reported authorization of $30 million share repurchase program.
    • Peloton Interactive, Inc. (NASDAQ:PTON) jumped 11.9% to close at $22.61. Bernstein initiated coverage on Peloton Interactive with an Outperform rating and announced a price target of $40.
    • Wejo Group Limited (NASDAQ:WEJO) gained 10.5% to close at $3.70.
    • Hycroft Mining Holding Corporation (NASDAQ:HYMC) shares gained 9.4% to settle at $1.52 after dipping 26% on Monday.
    • AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) rose 8.5% to close at $4.98. AVEO Pharmaceuticals, on Monday, posted a Q4 loss of $0.21 per share.
    • Wayfair Inc (NYSE:W) gained 7.6% to settle at $112.80.
    • AerSale Corporation (NASDAQ:ASLE) shares gained 6.1% to close at $15.22 after the company reported better-than-expected Q4 adjusted EPS and sales results.

     

    Losers

    • Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) shares tumbled 43.1% to close at $1.70 on Tuesday after the company reported Q4 results and issued weak FY22 sales outlook. Stifel downgraded Evolv Technologies from Buy to Hold and lowered the price target from $10 to $2.
    • Cepton, Inc. (NASDAQ:CPTN) dipped 28.8% to close at $4.28.
    • Four Seasons Education (Cayman) Inc. (NYSE:FEDU) dropped 26.4% to close at $0.3754
    • Better Therapeutics, Inc. (NASDAQ:BTTX) fell 23% to close at $3.12. Better Therapeutics said data from its pivotal trial of BT-001, an investigational PDT platform that is designed to use digitally delivered nCBT to treat type 2 diabetes, demonstrated clinically meaningful and statistically significant results in improving glycemic control by reducing A1c 0.4% versus the control group receiving standard of care.
    • The Very Good Food Company Inc. (NASDAQ:VGFC) dropped 20.1% to close at $0.5316.
    • Yield10 Bioscience, Inc. (NASDAQ:YTEN) dipped 19.8% to settle at $4.55.
    • Coupa Software Incorporated (NASDAQ:COUP) shares fell 19.2% to close at $72.55 after the company reported Q4 results and issued Q1 forecast.
    • Taoping Inc. (NASDAQ:TAOP) fell 19.2% to close at $1.14.
    • ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) fell 18.7% to settle at $29.01 after the company reported downbeat Q4 earnings and issued weak FY22 sales forecast.
    • Red Cat Holdings, Inc. (NASDAQ:RCAT) dropped 18.3% to close at $2.23. Red Cat, on Monday, announced its subsidiary Teal Drones has been selected by the Department of Defense's Defense Innovation Unit and U.S. Army to compete in the Short Range Reconnaissance Tranche 2 Program of Record.
    • China Natural Resources, Inc. (NASDAQ:CHNR) fell 17.9% to close at $0.87.
    • Bon Natural Life Limited (NASDAQ:BON) dropped 17.4% to close at $2.95. Bon Natural Life recently reported FY21 earnings results.
    • Save Foods, Inc. (NASDAQ:SVFD) dipped 17.3% to close at $5.47.
    • iPower Inc. (NASDAQ:IPW) dropped 16.7% to settle at $1.35.
    • Precision BioSciences, Inc. (NASDAQ:DTIL) fell 16.4% to close at $2.96 following FY21 results.
    • Avinger, Inc (NASDAQ:AVGR) fell 15.8% to close at $3.03.
    • Natera, Inc. (NASDAQ:NTRA) dropped 15.5% to close at $30.32.
    • Pingtan Marine Enterprise Ltd. (NASDAQ:PME) fell 14.4% to close at $0.5524.
    • Imperial Petroleum Inc. (NASDAQ:IMPP) fell 13.6% to $2.9699.
    • Mammoth Energy Services, Inc. (NASDAQ:TUSK) dropped 11.9% to close at $1.78.
    • Verve Therapeutics, Inc. (NASDAQ:VERV) shares fell 11.7% to settle at $21.00. Verve Therapeutics, on Monday, posted Q4 loss of $0.65 per share.
    • Agrify Corporation (NASDAQ:AGFY) fell 10.1% to close at $4.62. Agrify recently entered into a debt financing agreement for up to $135 million in a senior secured note facility with an institutional lender.
    • ION Geophysical Corporation (NYSE:IO) fell 9.3% to close at $0.9160.
    • Houston American Energy Corp. (NASDAQ:HUSA) fell 8% to close at $5.75.
    • Prelude Therapeutics Incorporated (NASDAQ:PRLD) fell 7.7% to close at $7.15. B of A Securities downgraded Prelude Therapeutics from Buy to Neutral and lowered the price target from $50 to $10.
    Get the next $AGFY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGFY
    $AHPI
    $ANIP
    $ASLE

    CompanyDatePrice TargetRatingAnalyst
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026Outperform → Perform
    Oppenheimer
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026$20.00Neutral → Underperform
    BofA Securities
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Wayfair Inc.
    $W
    2/20/2026$114.00 → $105.00Overweight
    Analyst
    Fossil Group Inc.
    $FOSL
    2/19/2026$7.00Outperform
    Northland Capital
    Kingsoft Cloud Holdings Limited
    $KC
    2/11/2026$15.60Neutral → Buy
    Goldman
    Peloton Interactive Inc.
    $PTON
    2/10/2026Buy → Hold
    Argus
    Peloton Interactive Inc.
    $PTON
    2/6/2026$8.00 → $6.00Market Perform
    Telsey Advisory Group
    More analyst ratings

    $AGFY
    $AHPI
    $ANIP
    $ASLE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Sprott Eric bought $6,307,500 worth of shares (150,000 units at $42.05) (SEC Form 4)

    4 - HYCROFT MINING HOLDING CORP (0001718405) (Issuer)

    2/23/26 6:34:48 PM ET
    $HYMC
    Precious Metals
    Basic Materials

    Large owner Sprott Eric bought $9,198,000 worth of shares (200,000 units at $45.99) (SEC Form 4)

    4 - HYCROFT MINING HOLDING CORP (0001718405) (Issuer)

    1/30/26 8:35:50 PM ET
    $HYMC
    Precious Metals
    Basic Materials

    Large owner Sprott Eric bought $4,996,000 worth of shares (100,000 units at $49.96) (SEC Form 4)

    4 - HYCROFT MINING HOLDING CORP (0001718405) (Issuer)

    1/27/26 9:16:28 PM ET
    $HYMC
    Precious Metals
    Basic Materials

    $AGFY
    $AHPI
    $ANIP
    $ASLE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-6) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 12/28/2021. Application Category: NDA, Application Number: 210132, Application Classification: Efficacy

    12/29/21 7:23:57 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for IMVEXXY issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug IMVEXXY (SUPPL-2) with active ingredient ESTRADIOL has changed to 'Approval' on 11/16/2021. Application Category: NDA, Application Number: 208564, Application Classification: Labeling

    11/17/21 4:38:32 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:22:37 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGFY
    $AHPI
    $ANIP
    $ASLE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PROCEPT BioRobotics downgraded by Oppenheimer

    Oppenheimer downgraded PROCEPT BioRobotics from Outperform to Perform

    2/26/26 7:23:22 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics downgraded by BofA Securities with a new price target

    BofA Securities downgraded PROCEPT BioRobotics from Neutral to Underperform and set a new price target of $20.00

    2/26/26 7:11:50 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGFY
    $AHPI
    $ANIP
    $ASLE
    SEC Filings

    View All

    SEC Form S-8 filed by Butterfly Network Inc.

    S-8 - Butterfly Network, Inc. (0001804176) (Filer)

    2/27/26 9:19:56 AM ET
    $BFLY
    Medical Electronics
    Health Care

    SEC Form 10-K filed by Butterfly Network Inc.

    10-K - Butterfly Network, Inc. (0001804176) (Filer)

    2/27/26 8:04:55 AM ET
    $BFLY
    Medical Electronics
    Health Care

    SEC Form 10-K filed by ANI Pharmaceuticals Inc.

    10-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)

    2/27/26 6:59:42 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGFY
    $AHPI
    $ANIP
    $ASLE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Founder Conine Steven sold $2,125,377 worth of shares (26,950 units at $78.86), decreasing direct ownership by 14% to 169,073 units (SEC Form 4)

    4 - Wayfair Inc. (0001616707) (Issuer)

    2/27/26 4:50:41 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    Chief Executive Officer Shah Niraj sold $2,129,850 worth of shares (27,000 units at $78.88), decreasing direct ownership by 14% to 169,137 units (SEC Form 4)

    4 - Wayfair Inc. (0001616707) (Issuer)

    2/27/26 4:48:18 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    Co-Founder Conine Steven sold $6,944,261 worth of shares (93,050 units at $74.63), decreasing direct ownership by 32% to 196,023 units (SEC Form 4)

    4 - Wayfair Inc. (0001616707) (Issuer)

    2/25/26 5:39:31 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AGFY
    $AHPI
    $ANIP
    $ASLE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

    11 scientific abstracts, including 4 oral presentations and a concurrent publication in Nature Medicine, underscore how Signatera MRD can improve quality of life for patients with genitourinary cancers Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026. Across four oral presentations in muscle-invasive bladder cancer (MIBC), these data reinforce Signatera's role in identifying patients who benefit from adjuvant immunotherapy, supporting response-adaptive bladder p

    2/27/26 10:05:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

    Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectivelyQuarterly and full year ILUVIEN® and YUTIQ® net revenues of $19.8 million and $74.9 million, respectively(1) Quarterly and full year GAAP net income available to common shareholders of $27.5 million and $77.2 million, respectivelyRecord quarterly and full year adjusted non-GAAP EBIT

    2/27/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapid Micro Biosystems to Present at TD Cowen 46th Annual Health Care Conference

    LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the TD Cowen 46th Annual Health Care Conference in Boston, MA. The Company is scheduled to present on Tuesday, March 3 at 10:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived

    2/26/26 4:15:00 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AGFY
    $AHPI
    $ANIP
    $ASLE
    Financials

    Live finance-specific insights

    View All

    ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

    Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectivelyQuarterly and full year ILUVIEN® and YUTIQ® net revenues of $19.8 million and $74.9 million, respectively(1) Quarterly and full year GAAP net income available to common shareholders of $27.5 million and $77.2 million, respectivelyRecord quarterly and full year adjusted non-GAAP EBIT

    2/27/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Natera Reports Fourth Quarter and Full Year 2025 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Recent Financial Highlights Generated total revenues of $665.5 million in the fourth quarter of 2025, compared to $476.1 million in the fourth quarter of 2024, an increase of 39.8%. Product revenues grew 39.8% over the same period. Generated a gross margin1 of 66.9% in the fourth quarter of 2025, compared to a gross margin1 of 62.9% in the fourth quarter of 2024. Generated total revenues of $2,306.1 million in the full year 2025, compared to $1,696.9 million in the full year 2024, an increase of 35.9%.

    2/26/26 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Butterfly Network Reports Fourth Quarter 2025 Financial Results

    Delivered Record Annual and Quarterly Revenue Reported quarterly record Revenue of $31.5 million in Q4, representing 41% YoY growth Generated positive net cash flow of $6.3 million in Q4 and lowest annual cash usage in company history Midjourney partnership contributed $6.8 million of revenue in Q4, advancing Butterfly Embedded™ platform strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Joseph DeVivo, Butterfly's Presiden

    2/26/26 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $AGFY
    $AHPI
    $ANIP
    $ASLE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Kaival Brands Innovations Group Inc.

    SC 13D/A - Kaival Brands Innovations Group, Inc. (0001762239) (Subject)

    12/12/24 7:22:30 PM ET
    $KAVL
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolv Technologies Holdings Inc.

    SC 13G/A - Evolv Technologies Holdings, Inc. (0001805385) (Subject)

    12/12/24 3:21:41 PM ET
    $EVLV
    Computer peripheral equipment
    Technology

    Amendment: SEC Form SC 13G/A filed by Red Cat Holdings Inc.

    SC 13G/A - Red Cat Holdings, Inc. (0000748268) (Subject)

    12/6/24 4:32:04 PM ET
    $RCAT
    Computer Software: Prepackaged Software
    Technology

    $AGFY
    $AHPI
    $ANIP
    $ASLE
    Leadership Updates

    Live Leadership Updates

    View All

    CISO Global Appoints Dhaval Damania as EVP of Cybersecurity & IT

    Experienced AI and enterprise IT operations leader joins Company to accelerate scalable growth, strengthen security architecture, and advance next-generation cyber software innovation Scottsdale, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO) ("CISO Global" or the "Company"), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Dhaval Damania as Executive Vice President of Cybersecurity & IT. This appointment reinforces its continued commitment to operational excellence, innovation, and scalable growth across its next-generation cybersecurity software portfolio. In this role, Damania will lead CISO Global's

    2/23/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    CISO Global Lands 30 Year Sales Veteran Michael Czerneda to Ignite the Next Wave of Software Growth

    New Vice President of Sales to accelerate software-driven growth across cyber services platform and insurance distribution channels  Scottsdale, Ariz., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO) ("CISO Global" or the "Company"), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Michael Czerneda as Vice President of Sales. In this role, Czerneda will lead enterprise-wide sales initiatives as the Company accelerates its transition toward scalable, software-driven growth built on its established cyber services platform.  Czerneda brings more than 30 years of sales leadership experience spanning UCaaS, CCaaS, da

    2/18/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care